Cargando…

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors

SIMPLE SUMMARY: Neuroendocrine neoplasms (NENs) are rare and heterogeneous tumors, presenting in often challenging clinical scenarios, and require multidisciplinary discussion for optimal care. The theranostic approach (DOTA peptides labelled with (68)Ga for imaging well-differentiated neuroendocrin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ambrosini, Valentina, Zanoni, Lucia, Filice, Angelina, Lamberti, Giuseppe, Argalia, Giulia, Fortunati, Emilia, Campana, Davide, Versari, Annibale, Fanti, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870358/ https://www.ncbi.nlm.nih.gov/pubmed/35205805 http://dx.doi.org/10.3390/cancers14041055

Ejemplares similares

New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms
por: Fortunati, Emilia, et al.
Publicado: (2022)

Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience
por: Filice, A., et al.
Publicado: (2012)

[68Ga]Ga-DOTANOC Uptake at Pancreatic Head/Uncinate Process: Is It a Persistent Diagnostic Pitfall Over Time?
por: Tabacchi, Elena, et al.
Publicado: (2022)

Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors
por: Calabrò, Diletta, et al.
Publicado: (2020)

(18)F-FDG and (68)Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study
por: Taralli, Silvia, et al.
Publicado: (2018)

SPECT/CT with radiolabeled somatostatin analogues in the evaluation of systemic granulomatous infections
por: Monteiro, Paulo Henrique Silva, et al.
Publicado: (2017)

Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [(64)Cu]Cu-DOTA-TOC
por: Vahidfar, Nasim, et al.
Publicado: (2022)

Is there a clinical usefulness for radiolabeled somatostatin analogues beyond the consolidated role in NETs?
por: Cuccurullo, Vincenzo, et al.
Publicado: (2017)

PET and PET/CT with (68)Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors
por: Sollini, Martina, et al.
Publicado: (2014)

Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT
por: Durmo, Rexhep, et al.
Publicado: (2022)

Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.
por: O'Byrne, K. J., et al.
Publicado: (1994)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
por: Stueven, Anna Kathrin, et al.
Publicado: (2019)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

Metastatic Insulinoma Managed with Radiolabeled Somatostatin Analog
por: Costa, Ricardo, et al.
Publicado: (2013)

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
por: Kiesewetter, B., et al.
Publicado: (2022)

Role of [(18)F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors
por: Magi, Ludovica, et al.
Publicado: (2022)

Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
por: Ge, Wenhao, et al.
Publicado: (2018)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2019)

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
por: Eychenne, Romain, et al.
Publicado: (2020)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
por: Appetecchia, Marialuisa, et al.
Publicado: (2010)

The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells
por: Li, Su-Chen, et al.
Publicado: (2012)

Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors
por: Gabrielsen, Jordan, et al.
Publicado: (2019)

Correction: Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2020)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
por: Rustgi, Sheila D., et al.
Publicado: (2021)

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
por: Sebastian-Valles, Fernando, et al.
Publicado: (2023)

The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
por: Panzuto, Francesco, et al.
Publicado: (2022)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals
por: Fani, Melpomeni, et al.
Publicado: (2022)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
por: Ström, Torbjörn, et al.
Publicado: (2019)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
por: Saksis, Rihards, et al.
Publicado: (2023)

Radiotherapy Planning and Molecular Imaging in Lung Cancer
por: Filice, Angelina, et al.
Publicado: (2020)

Effects of somatostatin analogs on uptake of radiolabeled somatostatin analogs on imaging: a systematic review and meta-analysis
por: Wang, Rang, et al.
Publicado: (2023)

The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?
por: Lamberti, Giuseppe, et al.
Publicado: (2018)

SAT-LB24 Association of Expression of Somatostatin Receptor 2 Subtype in Non-Pituitary Neuroendocrine Tumors With Response to Treatment With Somatostatin Analogues
por: Siddiqui, Abdullah, et al.
Publicado: (2020)

A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs
por: Crespo-Jara, Aurora, et al.
Publicado: (2016)

Molecular Imaging of Vulnerable Coronary Plaque with Radiolabeled Somatostatin Receptors (SSTR)
por: Anzola, Luz Kelly, et al.
Publicado: (2021)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Kwekkeboom, D. J., et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_m6rti5c1s3qjbec8e0tq9ve10u